Skip to main content
← All trials
Delayed Graft FunctionKidney and urinaryDrugPhase 3

What this study is

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

What's being tested

  • Ravulizumab

    Intervention · DRUG

    Participants will receive ravulizumab via intravenous (IV) infusion.

  • Placebo

    Intervention · DRUG

    Participants will receive placebo via intravenous (IV) infusion.

Study details

Official title
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Sponsor
Alexion Pharmaceuticals, Inc.
Conditions
Delayed Graft Function · DGF · Kidney Transplant
Enrolling
450 people
Starts
2025-05-19
Est. completion
2028-11-06
Design
Quadruple-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗